Market Overview

UPDATE: JP Morgan Downgrades United Therapeutics to Underweight

Related UTHR
Stocks Hitting 52-Week Lows
United Therapeutics Says Informed by Medtronics that FDA issued Response Letter Indicating PMA is Not Approvable; UTHR Expects FDA Action in 2016 Regarding NDA Seeking FDA Approval of New Labeling for Remodulin
Why Is It A Good Time To Buy United Therapeutics Corporation? (Seeking Alpha)

JP Morgan reduced its rating on United Therapeutics (NASDAQ: UTHR) from Neutral to Underweight and lowered its price target from $50 to $40.

JP Morgan commented, "We're moving to Underweight from Neutral on UTHR shares and lowering our Dec 2013 target to $40 from $50 on the back of yesterday's complete response letter (CRL) by FDA on oral Remodulin. While we recognize that oral Remodulin wasn't assumed in a lot of Street models (including ours), it was somewhat reflected in valuation and is it essentially the company's only upside driver over a 2+ year period. Given the rationale for the CRL, it doesn't seem to us that oral is approvable in the US or EU, at least not in the next 3-4 years."

United Therapeutics closed at $53.28 on Tuesday.

Latest Ratings for UTHR

Apr 2016Ladenburg ThalmannDowngradesBuyNeutral
Feb 2016BarclaysMaintainsEqual-weight
Feb 2016Standpoint ResearchUpgradesHoldBuy

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (UTHR)

View Comments and Join the Discussion!